Fig. 2

Incidence of composite endpoints according to abnormal vs. normal regadenoson stress CMRs. Panel a outlines the rates of the composite endpoint according to abnormal vs. normal regadenoson stress CMRs. Kaplan-Meier curves in Panel b demonstrate that cumulative incidence estimate of the composite endpoint is significantly higher in patients with abnormal vs. normal regadenoson stress CMRs